dr. pennell on the use of brigatinib in alk nsclc
Published 4 years ago • 77 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
2:12
dr. pennell on the evolution of targeted treatment in nsclc
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
1:38
dr. drilon on the safety profile of brigatinib in alk nsclc
-
2:22
dr. pennell on the evolution of targeting her2 in lung cancer
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
1:39
dr. leach on brigatinib in alk-positive nsclc
-
1:41
dr. pennell on remaining challenges in nsclc
-
4:01
use of brigatinib in alk nsclc & future
-
1:39
dr. pennell on benefits of liquid biopsies in lung cancer
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
0:52
dr. rotow on remaining questions with brigatinib in alk nsclc
-
4:37
fda approval of brigatinib for alk nsclc
-
2:10
dr. pennell on importance of egfr testing in nsclc
-
1:11
dr. rotow on brigatinib safety profile in alk nsclc
-
2:13
alk nsclc: brigatinib indication and alta trial
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
1:14
dr. rotow on first-line brigatinib versus crizotinib in alk nsclc
-
6:51
progression in alk nsclc after frontline therapy